FIND is a Swiss foundation that develops, evaluates and accelerates the implementation of new diagnostic tools for poverty-related diseases such as TB, malaria and sleeping sickness.
The goal of the research alliance agreement is to establish a series of heat-stable HuCAL-based antibodies as key components of novel diagnostic tests that are robust in tropical climates.
Using MorphoSys's proprietary HuCAL technology, AbD Serotec will identify heat-stable fully human antibodies specific for rapid diagnostic test applications for parasite detection.
Under the terms of the agreement, FIND receives the rights for the commercial use of heat-stable HuCAL-derived antibodies for in vitro diagnostics. AbD Serotec will participate in sales of diagnostic tests using such antibodies in industrialised countries.
The collaboration could be expanded to cover other disease areas of relevance for FIND's objectives.
Comments on this story may be sent to admin@m2.com

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index